tirzepatide and kidney SURPASS-CVOT: Significantly Reduces Major Events Compared to Dulaglutide in T2D Not currently a kidney therapy.

As use continues to grow, emergency physicians will encounter these medications more frequently across a broader patient population

Cost, Insurance Driving Move to Compounded Drugs Compounded GLP-1 medications are not approved by the FDA, and the agency issued a warning in June calling them potentially "risky for patients." This hasn't stopped patients from switching to the unapproved drugs, and 35% of patients who took compounded GLP-1s left from a name brand drug, according to Gallup

Angst et al

But lets assume $120M of compounded GLP-1 Revenue per quarter in 2026

But despite their frequent association they're combined in the GLOW Blend, KLOW Blend, and many research protocols they are fundamentally different compounds with distinct mechanisms, structures, and research applications